Robust clinical trial data are proving to be fundamental in shaping investor confidence and driving strategic decisions in the biotechnology sector. Between 2015 and 2020 alone, biotech investments have heavily favored companies with advanced clinical-stage candidates, underscoring the close link between science and capital.
Evaluating a biotech company’s clinical pipeline and trial maturity is often more insightful than financials alone. At Axcellant, we see this impact firsthand: from designing robust Phase II studies to supporting pivotal Phase III trials, we’re helping biotech innovators translate scientific promise into commercial value.
Curious about how clinical strategy can align with business success? Let’s continue the conversation.
Read the full article (in Polish) here.
Axcellant is pleased to announce the formation of its Advisory Board - a group of distinguished experts in clinical science,…
The FDA and the European Commission are changing the rules of the game simultaneously. The shift is from a single…
Modern nuclear medicine is a high-tech discipline that requires advanced facilities, infrastructure, qualified staff, and know-how. The reliable supply of radionuclides,…
Copyright @ 2026 Axcellant